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Abstract
Purpose To study the possible pharmacokinetic and
pharmacodynamic interactions between irinotecan and
methimazole.
Methods A patient treated for colorectal cancer with sin-
gle agent irinotecan received methimazole co-medication
for Graves’ disease. Irinotecan pharmacokinetics and side
eVects were followed during a total of four courses (two
courses with and two courses without methimazole).
Results Plasma concentrations of the active irinotecan
metabolite SN-38 and its inactive metabolite SN-38-
Glucuronide were both higher (a mean increase of 14 and
67%, respectively) with methimazole co-medication,
compared to irinotecan monotherapy. As a result, the mean
SN-38 glucuronidation rate increased with 47% during
concurrent treatment. Other possible confounding factors
did not change over time. SpeciWc adverse events due to
methimazole co-treatment were not seen.
Conclusions Additional in vitro experiments suggest that
these results can be explained by induction of UGT1A1 by
methimazole, leading to higher SN-38G concentrations.
The prescribed combination of these drugs may lead to
highly toxic intestinal SN-38 levels. We therefore advise
physicians to be very careful in combining methimazole
with regular irinotecan doses, especially in patients who are
prone to irinotecan toxicity.
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Abbreviations
APC 7-Ethyl-10-[4-N-(5-aminopentanoic acid)-
1-piperidino]-carbonyloxy-camptothecin
CES Carboxylesterases
CYP3A Cytochrome P450 3A isoforms
NPC 7-Ethyl-10-[4-amino-1-piperidino]-carbonyl-
oxycamptothecin
SN-38 7-Ethyl-10-hydroxy camptothecin
SN-38G Glucuronide form of SN-38
UGT1A Uridine diphosphate glucuronosyltransferase
1A isoforms
Introduction
Irinotecan is extensively used in the treatment of advanced
colorectal cancer [1]. It is a pro-drug of the active com-
pound SN-38 and is metabolized by cytochrome P450 3A
(CYP3A) into inactive metabolites (Fig. 1a). In the liver,
uridine diphosphate glucuronosyltransferase 1A (UGT1A)
is capable of inactivating SN-38 to its glucuronide form
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SN-38G, which facilitates excretion from the circulation
[2]. In the intestines, SN-38G can be transformed back into
SN-38 by bacterial -glucuronidase. The metabolism of iri-
notecan is complicated by several drug-transporting proteins
involved in the elimination of the drug (i.e. ATP-binding cas-
sette transporters) [3]. Besides genetic alterations in the
UGT1A gene, also environmental factors are known to
inXuence its metabolism [3–5]. For instance, cigarette
smoking may induce its metabolism, thereby decreasing the
systemic exposure to SN-38 [6].
Here, we report on a patient who used methimazole
while being treated with irinotecan chemotherapy. We
hypothesized that methimazole could seriously inXuence
irinotecan metabolism, as pre-clinical data suggest that
methimazole inhibits CYP3A [7] and induces certain
UGT1A subtypes [8], both being crucial enzyme systems
Fig. 1 Pharmacokinetics of 
irinotecan and metabolites. 
a Irinotecan is converted into its 
1,000 times more active metabo-
lite SN-38 by carboxylesterases 
(CES), which are predominately 
found in the liver. The aYnity 
for this reaction is low, since 
only a fraction of irinotecan is 
directly converted into SN-38. 
Competing with the formation of 
SN-38 is the CYP3A-mediated 
inactivation of irinotecan into 
the metabolites APC and NPC. 
In turn, carboxylesterases also 
have the ability to convert both 
of these compounds into SN-38. 
SN-38 is glucuronidated by 
UGT1A into its inactive metabo-
lite SN-38G. In the intestines, 
-glucuronidase-producing 
bacteria can reverse this latter 
reaction, and thus reactivate 
SN-38, which causes the 
dose-limiting toxicity diarrhea. 
Area under the plasma concen-
tration versus time curves for iri-
notecan (b), NPC (c), APC (d), 
SN-38 (e), and SN-38G 
(f) during all four chemotherapy 
courses. The open and closed 
symbols describe the two cours-
es with methimazole and the two 
courses without methimazole 
co-treatment, respectively
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involved in the elimination of irinotecan and its metabo-
lites. By performing additional in vitro experiments, we
tested our hypothesis.
Materials and methods
Our patient was a cigarette smoking 53-year-old male, with
locally advanced colorectal cancer. Six months prior to the
start of irinotecan treatment, he was treated for hyperthy-
roidism due to Graves’ disease using a combination of
methimazole and levothyroxine. Other daily medicines
were acetaminophen, fentanyl, pantoprazole, carbasalate
calcium, metoclopramide, and dexamethasone. During two
3-weekly courses of irinotecan, the patient took a daily
dose of 30 mg methimazole. Two weeks after the second
chemotherapy course, methimazole was stopped and the
patient was treated with radioiodine (I-131) as a deWnitive
treatment for Graves’ hyperthyroidism. Without delay, the
following courses of irinotecan were administered. After
written informed consent, plasma pharmacokinetics of iri-
notecan and its metabolites were collected during a total of
four courses. Patient-related factors (i.e. co-medication,
smoking status), laboratory values and toxicities were
closely monitored, UGT1A1*28 genotype was determined,
and active hormone 3,5,3-triiodothyronine (T3), and thy-
roid stimulating hormone (TSH, thyrotropin) levels were
determined to exclude possible confounding eVects of vary-
ing thyroid status.
During and after the 90-min intravenous infusions of iri-
notecan (350 mg/m2), blood was drawn at speciWc time-
points [6]. Plasma concentrations of irinotecan, NPC, APC,
SN-38, and SN-38G were determined using validated chro-
matography methods [9, 10]. Individual plasma pharmaco-
kinetics were estimated using non-compartmental analyses
(WinNonLin 5.0, Pharsight, CA). At weekly outpatient vis-
its, toxicities were scored.
Methods for the additional in vitro experiments are
described in detail in the “Appendix” section.
Results
The area under the plasma concentration–time curve
(AUC) of irinotecan did not diVer between the courses with
or without methimazole co-treatment (mean 16.1 g £ h/mL;
Fig. 1b; Table 1). However, plasma concentrations of both
SN-38 and SN-38G were higher during the courses with
methimazole (Fig. 1e, f). With methimazole, the mean SN-
38 AUC was 14% higher than without methimazole
(125 ng £ h/mL vs. 110 ng £ h/mL). In the presence of
methimazole, the mean SN-38G AUC was 67% higher
(1,255 ng £ h/mL vs. 753 ng £ h/mL). Consequently, a
mean 47% increased relative extent of glucuronidation,
which is the ratio of SN-38G over SN-38 (mean, 10.1 vs.
6.85), was found during the combination treatment courses.
The exposure to the CYP3A metabolites APC (mean
3,018 ng £ h/mL; Fig. 1d) and NPC (mean 32.3 ng £ h/mL;
Fig. 1c) was not diVerent between the courses with or with-
out methimazole.
Except for methimazole, co-medication did not change
during the studied courses and also smoking behavior of
the patient (15–20 cigarettes per day) did not change.
The patient appeared to be wild-type (TA6/TA6) for
UGT1A1*28, meaning that UGT1A1 function was not
lowered based on this familiar genetic polymorphism [3].
Thyroid hormone levels varied during the assessed courses
(Table 1), with a transient but clear hyperthyroidism during
the fourth course. Nevertheless, a correlation between thy-
roid function and systemic chemotherapy levels could not
be established. Irinotecan-related toxicity was mild during
all courses. The absolute neutrophil count nadir was similar
in all courses (mean 4.2 £ 109/L).
In the in vitro experiments, simultaneous incubation of
human liver microsomes with irinotecan and methimazole
Table 1 Baseline characteristics, pharmacokinetics, chemistry, and
toxicities during four treatment courses with irinotecan
TSH Thyroid stimulating hormone, T3 active hormone 3,5,3-triiodo-
thyronine, AUC area under the plasma concentration versus time curve,
SN-38 active metabolite of irinotecan; SN-38G detoxiWed metabolite of
SN-38, REG relative extent of glucuronidation, AST aspartate amino-
transferase, ALT alanine aminotransferase
a Normal values between brackets. For TSH and T3, means of weekly
values within a period of 3 weeks have been given
b Grading according to National Cancer Institute—Common Termi-
nology Criteria for Adverse Events version 3.0
I r i n o t e c a n  c o u r s e 1234
Methimazole Yes Yes No No
TSH (0.4–4.3 mU/L)a 0.0 2.6 0.0 0.0
T3 (1.4–2.5 nmol/L) 1.54 2.11 2.14 2.86
Dose irinotecan (mg) 660 660 660 660
AUC(0–56 h) irinotecan (g £ h/mL) 16.6 16.0 15.8 16.0
AUC(0–56 h) APC (ng £ h/mL) 3,227 2,919 3,028 2,897
AUC(0–8 h) NPC (ng £ h/mL) 31.9 32.4 32.2 32.5
AUC(0–56 h) SN-38 (ng £ h/mL) 117 133 106 114
AUC(0–56 h) SN-38G (ng £ h/mL) 1,301 1,209 728 777
R E G 1 1 . 19 . 0 96 . 8 76 . 8 2
B i l i r u b i n  ( 0 – 1 6 U / L ) 5676
Alkaline phosphatase (0–119 U/L) 189 182 176 152
-Glutamyltransferase (0–49 U/L) 60 42 34 33
A S T  ( 0 – 3 6 U / L ) 2 02 11 81 6
A L T  ( 0 – 4 0 U / L ) 2 42 32 41 8
Neutrophil nadir (£109/L) 4.7 4.1 4.1 4.0
Diarrhea (grade)b 1000234 Cancer Chemother Pharmacol (2011) 67:231–236
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resulted in a slightly decreased formation of NPC and APC
(both 16% reduced compared to incubation in the absence
of methimazole; Appendix Fig. 2a). Control experiments in
which irinotecan was combined with Xuconazole, a known
potent CYP3A-inhibitor, resulted in a strong inhibition of
NPC and APC formation (78 and 74% inhibition, respec-
tively, compared to experiments in the absence of Xuconaz-
ole; Appendix Fig. 2a). No eVect of methimazole on SN-38
formation was noticed. In addition, SN-38G formation did
not decrease during the co-incubation of microsomes with
methimazole and SN-38, while a reduction of 43% was
observed during simultaneous incubation of SN-38 with the
UGT1A1 inhibitor ketoconazole.
In order to determine whether methimazole is capable of
inducing UGT1A1 expression, a HCT 116 colorectal carci-
noma cell-line was cultured in the presence of various con-
centrations of methimazole (25–100 M) for »48 h after
which UGT1A1 mRNA levels were measured by quantita-
tive RT-PCR. Appendix Fig. 2b displays the results of the
experiment showing a 15–18-fold induction of UGT1A1
mRNA levels by methimazole compared to untreated con-
trol cells. The lowest concentration of methimazole
(25 M) gave rise to the highest induction levels after 48 h,
whereas the higher concentrations (50 and 100 M) already
showed strongly elevated UGT1A1 levels after 24 h that
seem to return to normal in a concentration-dependent man-
ner after a longer incubation period.
Our in vitro tests in which the transport of mitoxantrone
by ABCG2 was studied showed that methimazole in con-
centrations up to 100 M did not aVect the eZux of
mitoxantrone. In contrast, the known ABCG2 inhibitor
Ko-143 reduced the eZux of mitoxantrone, thereby causing
accumulation of the drug.
Discussion
In the current case, factors known to signiWcantly alter iri-
notecan pharmacokinetics did not change over time, except
for the use of methimazole. As a relationship between thy-
roid status and plasma concentrations of chemotherapy was
not found, a possible inXuence of thyroid hormone on
UGT1A activity is probably very limited in our case [11].
Therefore, we assume that the intra-patient diVerences in
pharmacokinetics found over the courses are mainly attrib-
utable to methimazole.
Irinotecan drug-concentrations assessed in the courses
without methimazole are within the low-normal range of
literature data [6, 12, 13], possibly due to patients’ smoking
behavior. As SN-38 levels are only moderately increased,
while SN-38G concentrations are much higher in the
presence of methimazole, our clinical data support the pre-
clinical literature describing combined eVects of CYP3A-
inhibition and UGT1A-induction by methimazole [7,  8].
However, inhibition of CYP3A was not conWrmed by lower
systemic concentrations of NPC and APC in the courses
with methimazole. In addition, our in vitro experiments
could not determine an important eVect of methimazole on
CYP3A activity. Therefore, we have to conclude that the
involvement of CYP3A is probably limited in the observed
pharmacokinetic alterations during methimazole exposed
courses.
UGT1A induction in turn will lead to increased SN-38G
levels, catalyzing SN-38 transformation into SN-38G. This
is expressed by the higher glucuronidation rate during the
combination treatment. Although the exact mechanism of
irinotecan-induced delayed-onset diarrhea is unclear, there
is consensus that intestinal toxicity is caused by local reac-
tivation of SN-38 from SN-38G by -glucuronidase-pro-
ducing bacteria in the gut [14,  15]. Therefore, higher
SN-38G levels as a result of methimazole co-treatment
could potentially lead to more intestinal toxicity, since
higher systemic SN-38G concentrations could cause
increased intestinal SN-38 levels when SN-38G is excreted
in the gut and is de-glucuronidated by intestinal bacteria. This
was also shown in a population-pharmacokinetic model of iri-
notecan, in which the AUC of SN-38G was correlated with
diarrhea scores (P < 0.005) [16]. In addition, it was shown that
co-treatment with the antibiotic neomycin reduces the fecal
-glucuronidase activity and fecal SN-38G/SN-38 ratio,
thereby reducing the incidence of diarrhea [17].
In our view, it is plausible that the eVect of higher SN-
38G levels in our patient did not result in more diarrhea
because this patient already had a low pharmacokinetic and
toxicity proWle, most likely because of his smoking behav-
ior and wild-type UGT1A1*28 genotype [6]. However, in
patients who are more prone to toxicity, higher SN-38G
levels as a result of concomitant methimazole use, could
potentially lead to severe diarrhea.
One cannot formally rule out the possibility that addi-
tional mechanisms contribute to the observed clinical phe-
notype. For instance, methimazole might interfere with
ABC-transporters involved in the eZux of the irinotecan
metabolites, leading to accumulation of SN-38 and SN-
38G. However, there is no literature available indicating
that methimazole is a substrate or inhibitor of ABC-trans-
porters. Moreover, our experiments conWrmed that thera-
peutic concentrations of methimazole do not aVect
ABCG2-mediated transport.
Conclusions
Although the exact explanation for our Wndings is subject
for further study, the combination of irinotecan and
methimazole might potentially lead to increased toxicityCancer Chemother Pharmacol (2011) 67:231–236 235
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due to higher systemic SN-38 and SN-38G concentrations.
Reactivation of high concentrations SN-38G by bacterial
enzymes in the bowel is potentially dangerous in that
respect and could lead to local toxicity. We therefore advise
physicians to be careful in combining methimazole with
regular irinotecan doses, especially in patients who are
prone to irinotecan toxicity.
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Appendix
Methods of in vitro experiments
In vitro experiments were performed to study the eVects of
methimazole on the metabolism of irinotecan and SN-38.
Pooled human liver microsomes were incubated for 30 min
with irinotecan (10 M) in the presence or absence of meth-
imazole (37.5 M) or Xuconazole (25 M; CYP3A inhibi-
tor) based on the method described by Slatter et al. [18].
The experiment was performed on 4 separate occasions. In
each experiment, microsomal proteins (1 mg/mL) were
incubated in triplicate. In addition, pooled human liver
microsomes were incubated for 30 min with SN-38 (5 M)
in the presence or absence of methimazole (37.5 M) or
ketoconazole (25 M; UGT1A inhibitor) based on the
method described by Yong et al. [19]. This experiment was
performed on separate occasions, during which microsomal
proteins (0.8 mg/mL) were incubated in triplicate. Experi-
ments were terminated by the addition of a perchloric acid/
methanol solution. Irinotecan and metabolite concentra-
tions from these experiments were measured, using the
methods mentioned earlier (Fig. 2).
HCT116 colorectal carcinoma cells were cultured
in Glutamax™ containing Hepes-buVered RPMI 1640
medium supplemented with 10% fetal calf serum (Gibco
BRL, Paisley, UK), 100 U/mL penicillin and 100 g/mL
streptomycin at 37°C in a humidiWed atmosphere contain-
ing 5% CO2. HCT116 cultures of 60% conXuence were cul-
tured in the presence of methimazole (25, 50, and 100 M)
or 0.1% (v/v) MeOH as a solute control. After 5, 24 or 48 h,
total RNA was extracted using RNA-Bee (Tel-TEST
Temco, Inc. Friendswood, TX). Relative UGT1A1 mRNA
expression levels were measured by real-time RT-PCR
using the Taqman Universal Master mix and Assay-On-
Demand products from Applied Biosystems (UGT1A1
assay ID: Hs02511055-s1). The human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH assay ID: 4310884E;
VIC/TAMRA) was used for normalization. Reactions were
run on an ABI PRISM 7900 sequence detector system
(Applied Biosystems, Foster City, CA) using the following
cycling conditions: 50°C for 2 min, 95°C for 10 min fol-
lowed by 40 cycles of 95°C for 15 s, and 60°C for 1 min.
Hek293 cells transfected with pcDNA3 (HEK293/neo)
or wild-type BCRP/ABCG2-R482R (HEK293/R) were cul-
tured under similar conditions as HCT116. To investigate
whether ABCG2 activity is aVected by methimazole, we
analyzed the intracellular accumulation of mitoxantrone
Fig. 2 In vitro experiments. a EVects of methimazole (striped bars)
and Xuconazole (open bars) on the formation of NPC, APC, and SN-38
during co-incubation with irinotecan, and eVects of methimazole
(striped bars) and ketoconazole (open bars) on the formation of
SN38G during co-incubation with SN-38. The black bars represent the
formation of irinotecan metabolites in the absence of any (potential)
inhibitor. b Methimazole induces UGT1A1 mRNA levels. HCT116
cells were cultured in the presence or absence (control) of various con-
centrations of methimazole. At 5 (cross-hatched bar), 24 (hatched bar)
and 48 (white bar) hours total RNA was isolated and used to measure
UGT1A1 mRNA levels by quantitative RT-PCR (Taqman™). Depict-
ed is the expression of UGT1A1 compared to the control UGT1A1 lev-
els (black bar), which are arbitrarily set at 1. Error bars indicate
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(a well known ABCG2 substrate) in the presence of methima-
zole. A cell suspension of 106 cells of HEK293/neo or
HEK293/R in RPMI1640 medium without further supple-
ments was incubated in the presence of 3 M mitoxantrone
at 37°C for 90 min with or without the addition of 10, 25,
50, 100 M methimazole or 200 nM of the fumitremorgin
C analog Ko-143. The mitoxantrone accumulation (Xuores-
cence intensity) was determined by Xow cytometry as
described previously [20].
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